Naratriptan
| Evidence Level: L3 | Predicted Indications: 3 |
Table of Contents
Naratriptan: From Acute Migraine Treatment to Migraine with Brainstem Aura
One-Sentence Summary
Naratriptan is a triptan-class agent internationally used for the acute treatment of migraine attacks, though the local marketing authorisation and formal original-indication text are not available in this evidence pack (Naratriptan is not currently marketed under
taiwan_regulatory). The TxGNN model’s top prediction is Migraine with Brainstem Aura, but the supporting literature and pharmacological rationale indicate this is more likely a known safety signal (triptans are relatively/absolutely contraindicated in this migraine subtype) than a genuine new therapeutic opportunity, with only 0 clinical trials and 20 publications, none of which specifically study naratriptan in brainstem-aura migraine.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available in evidence pack (no local marketing authorisation on record); internationally, naratriptan is indicated for acute treatment of migraine attacks with or without aura |
| Predicted New Indication | Migraine with Brainstem Aura |
| TxGNN Prediction Score | 99.98% |
| Evidence Level | L3 |
| UK Market Status | Not marketed |
| Number of Marketing Authorisations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is flagged as a data gap for this drug. Based on known pharmacology, naratriptan is a selective 5-HT1B/1D receptor agonist, exerting its acute anti-migraine effect through cranial vasoconstriction and inhibition of trigeminovascular nociceptive transmission — a well-established mechanism shared across the triptan class.
However, the relationship between the original indication (migraine) and the predicted indication (migraine with brainstem aura, formerly termed basilar-type migraine) is not a straightforward disease-expansion story. Because triptans act via vasoconstriction, and migraine with brainstem aura is theoretically associated with vertebrobasilar circulation involvement, current clinical guidance (including AHS/AAN evidence assessments) lists this subtype as a relative or absolute contraindication for triptan use rather than an approved or plausible extension of use. In other words, the high TxGNN score here most likely reflects a strong knowledge-graph association driven by shared “migraine” terminology and receptor biology, rather than evidence of therapeutic benefit.
Consequently, this prediction should be interpreted primarily as a pharmacovigilance/safety signal worth verifying against the SmPC contraindications, not as a novel repurposing opportunity to pursue for efficacy development.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
None of the identified publications specifically studied naratriptan in migraine with brainstem aura; the list below reflects the closest available evidence on naratriptan and migraine-with-aura populations, provided for context.
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 10972634 | 2000 | RCT | Clinical Therapeutics | Randomised double-blind crossover comparing naratriptan vs sumatriptan for headache recurrence in recurrence-prone migraine patients |
| 25600718 | 2015 | Guideline/Evidence Assessment | Headache | AHS updated evidence assessment of pharmacological therapies for acute migraine, including triptans |
| 11264684 | 2001 | RCT | Headache | Randomised, double-blind, placebo-controlled study of naratriptan 1mg/2.5mg BID as short-term prophylaxis of menstrually associated migraine |
| 10961768 | 2000 | RCT (small) | Cephalalgia | Naratriptan administered during migraine prodrome for prevention of headache onset |
| 25841032 | 2015 | Cohort/Comparative | Neurology | Compared acute treatment outcomes (sumatriptan) in migraine with aura vs without aura — relevant context for aura-subtype triptan response |
| 15926020 | 2005 | Pilot study | Neurological Sciences | Open, non-comparative pilot study of naratriptan for short-term prophylaxis of pure menstrual migraine |
| 17578540 | 2007 | Open-label study | Headache | Long-term tolerability of naratriptan for short-term prevention of menstrually related migraine |
| 27910087 | 2017 | Review | Headache | Review of treatment options for menstrual migraine, including naratriptan |
| 16268666 | 2005 | Review | CNS Drugs | Review of triptan use, including naratriptan, in management of menstrual migraine |
| 14511276 | 2003 | Case series/Review | Headache | Managing intractable migraine with naratriptan |
UK Market Information
No marketing authorisations are recorded for naratriptan in this evidence pack; the drug is currently not marketed in this jurisdiction (0 licenses on file). Local SmPC/BNF entries should be checked directly for current UK marketed status (e.g. Naramig®) if this is being evaluated for clinical use.
Safety Considerations
Please refer to the SmPC and BNF for safety information. Report suspected adverse reactions via the Yellow Card Scheme.
Important note beyond the formal safety fields: the repurposing rationale for this prediction itself flags that triptans, including naratriptan, are conventionally listed as contraindicated or requiring caution in migraine with brainstem (basilar-type) aura due to theoretical vasospasm risk in the vertebrobasilar territory. This should be explicitly checked against the current SmPC contraindications section before any clinical consideration.
Conclusion and Next Steps
Decision: Hold
Rationale: This TxGNN prediction most plausibly reflects a pharmacological/safety association rather than a genuine efficacy-based repurposing opportunity — migraine with brainstem aura is conventionally treated as a caution/contraindication for triptans, not a target indication, and no clinical trials or disease-specific literature support use in this population. The two lower-ranked candidates (atrophoderma vermiculata, ulerythema ophryogenesis, both L5) have no mechanistic plausibility or evidence and are not viable leads.
To proceed, the following is needed:
- TFDA/MHRA-equivalent SmPC and labelled warnings/contraindications (currently a Blocking data gap, DG001)
- Formal mechanism of action documentation from DrugBank (High-priority data gap, DG002)
- Confirmation from the current SmPC on whether migraine with brainstem aura is a listed contraindication
- If pursued despite the above, a targeted literature/pharmacovigilance review specific to triptan use in brainstem-aura migraine populations before any further development
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.